Clariant


Pandemic sustaining the portfolio

31/07/20 -"Clariant did quite well in the pandemic as speciality chemicals have offerings to help manage the crisis better. This does not necessarily mean they are “bullet proof” chemicals but their ..."

Pages
50
Language
English
Published on
31/07/20
You may also be interested by these reports :
07/08/20
It looks as if Symrise just took a small break in Q1 before coming back in the fast lane pushed by the strong demand in Latin America and ...

04/08/20
DSM’s Q2 figures were strongly supported by Nutrition’s strong performance. Profitability could not be sustained as Materials could not get away from ...

02/08/20
Wacker’s reported figures confirmed our broad picture of the company. The weaker performance was mainly driven by lower volumes rather than lower ...

02/08/20
After the missing guidance in Q1, the company estimates EBIT will decline by around 25% yoy. Note that the press release also states that “the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO